DATA GRAPHICS | Data Byte
PRVs still pricey despite renewal
Two priority review vouchers have sold since the rare pediatric program was extended
April 29, 2026 8:49 PM UTC
Rocket’s announcement Tuesday that it would sell its rare pediatric disease priority review voucher (PRV) for $180 million shows that even though the program’s sunset has been delayed through at least 2029, the going rate remains above $150 million.
Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) earned the voucher from the late March approval of Kresladi marnetegragene autotemcel to treat leukocyte adhesion deficiency Type I...